Day Light for Ischemia

Ischemia is not the cause of the core lesion in the anterior lobe; lesions in the periphery of the lobe are most likely to cause ischemia. The lesions that cause a core necrosis are not the source of the infarct because the source of the infarct is not a core lesion in the right or left lobe. Rather, infarction occurs because of an embolic cascade.

The patient will usually have no previous symptoms and will be a fit or moderately active individual. The symptoms that occur as a result of ischemia are often subtle with symptoms that arise once the acute phase has passed. Because of the potential for the symptoms to be attributed to other illnesses, a thorough history and physical examination to rule out causes that are common will maximize diagnostic accuracy.

Stroke is most common in very old people, people who are disabled and who have undergone major surgery. The cause is believed to be stroke or a sudden arterial blockage caused by atherosclerotic plaque in the aorta.

The data indicated that the frequency of ischemia in the U.S (21% +/- 9%) was comparable to that seen in Europe (27%). There was, however, no difference between the genders. This information supports the notion that in the U.S, ischemia may not be a significant factor in determining morbidity and mortality.

Ischemia can arise from a number of mechanisms, including peripheral artery disease, myocardial infarction, embolism, kidney obstruction, stroke, and cardiac arrhythmia. Treatment of ischemia often includes reperfusion therapy.\n

Most ischemia is due to vascular disease, coronary artery disease, peripheral artery disease, or diabetes. Common treatments for ischemia include atherosclerotic medical treatments, revascularization interventions, and antiplatelet therapy. A systematic review of current evidence indicates that some of these treatments are more effective than others.

In terms of therapeutic strategies for repairing or replacing damaged myocardium, the results of these trials indicate that further research is needed. There is considerable potential for improved patient outcomes by combining drugs and device technology to treat ischemia for myocardial infarction, and that this new technology will likely be available before the end of this century.

In this review, only one study showed the effectiveness in decreasing disease progression of DLP therapy. The authors suggest that the most important parameter in any study of DLP using a clinical trial design as opposed to a clinical trial on DLP as a monotherapy, is the combination of two or three treatments together with DLP (if it can be used as a monotherapy). At present, in general, we advocate combination therapy with DLP.

Ischemia lasts in the brain up to 30 days. However, only 15% of acute ischemic stroke patients will experience transient aphasia with normal neurological examination. This may be due to the presence of large proximal vessel occlusion. In a small minority of cases, the presence of a persistent deficit may be the result of delayed tissue death and not of ischemic damage.

Patients who report that they have more difficulty falling asleep or with noctrainers in the early morning should be particularly alarmed about day light exposure.

The data on the effect of light exposure on endothelial function and blood pressure have been reported in a recent report. Results from a recent clinical trial clearly suggest that the most promising therapeutic uses of the light radiation are the cosmetic effects such as skin rejuvenation and anti-aging and the therapeutic benefits of treatment of blood pressure and arterial thrombosis. These new cosmetic/therapeutic uses are still the subjects of further investigation.